Lachiewicz, Ave M. http://orcid.org/0000-0002-2934-3088
Stackhouse, Tracy M. http://orcid.org/0000-0001-6540-803X
Burgess, Kristin
Burgess, Debra
Andrews, Howard F. http://orcid.org/0000-0002-7726-0551
Choo, Tse-Hwei http://orcid.org/0000-0001-5068-9799
Kaufmann, Walter E. http://orcid.org/0000-0002-8561-8453
Kidd, Sharon A. http://orcid.org/0000-0002-7562-8682
Funding for this research was provided by:
Centers for Disease Control and Prevention (U01DD000231, U01DD000753, U01DD001189)
North Carolina Civitans East
Don Bower Fund
Knights of Columbus Operation Lamb, Inc.
Article History
Accepted: 6 September 2023
First Online: 16 October 2023
Declarations
:
: WEK: Chief Scientific Officer, Anavex Life Sciences Corp.; consultant to Tetra Therapeutics. The other co-authors have no competing interests to declare.